Cutler Group’s Travere Therapeutics TVTX Stock Holding History

Cutler Group’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-19,600	Closed	-$4K	–	6097
2021 Q3	$4K	Buy	+19,600	New	+$360K	﹤0.01%	4681
2019 Q2	–	Sell	-20,400	Closed	-$5K	–	4819
2019 Q1	$5K	Buy	+20,400	New	+$451K	﹤0.01%	2953
2018 Q1	–	Sell	-4,000	Closed	-$2K	–	5235
2017 Q4	$2K	Hold	4,000	–	–	﹤0.01%	4223
2017 Q3	$1K	Hold	4,000	–	–	﹤0.01%	5567
2017 Q2	$4K	Buy	4,000 +800	+25%	+$14.5K	﹤0.01%	5092
2017 Q1	$6K	Sell	3,200 -600	-16%	-$11.7K	﹤0.01%	4598
2016 Q4	$13K	Sell	3,800 -26,200	-87%	-$536K	﹤0.01%	3926
2016 Q3	$15K	Buy	30,000 +26,700	+809%	+$508K	﹤0.01%	3739
2016 Q2	$2K	Sell	3,300 -26,300	-89%	-$426K	﹤0.01%	5764
2016 Q1	$37K	Sell	29,600 -10,000	-25%	-$152K	﹤0.01%	2640
2015 Q4	$101K	Buy	+39,600	New	+$791K	0.01%	1763

Other funds holding TVTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Cutler Group's TVTX Position: Q1 2024 in Review

Cutler Group reduced its Travere Therapeutics (TVTX) stake by 30% in Q1 2024, selling an estimated $5.06K and leaving 1,400 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #1290.

Cutler Group first reported a position in TVTX in Q4 2015 and has held it in 26 quarters since. The position peaked at $482K in Q4 2015. 175 funds tracked by Wall St. Rank hold TVTX as of Q1 2024.

Cutler Group held 1,400 shares of Travere Therapeutics worth $10K as of Q1 2024.
Cutler Group sold 600 Travere Therapeutics shares in Q1 2024, an estimated $5.06K.
Travere Therapeutics made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #1290 holding.
Cutler Group first reported a position in Travere Therapeutics in Q4 2015 and has held it in 26 quarters since.
Cutler Group's Travere Therapeutics position peaked at $482K in Q4 2015.
175 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.